Broadly protective Shigella vaccine based on type III secretion apparatus proteins

Francisco J. Martinez-Becerra, Julian M. Kissmann, Jovita Diaz-Mcnair, Shyamal P. Choudhari, Amy M. Quick, Gabriela Mellado-Sanchez, John D. Clements, Marcela F. Pasetti, Wendy L. Picking

Research output: Contribution to journalArticlepeer-review

121 Scopus citations

Abstract

Shigella spp. are food- and waterborne pathogens that cause severe diarrheal and dysenteric disease associated with high morbidity and mortality. Individuals most often affected are children under 5 years of age in the developing world. The existence of multiple Shigella serotypes and the heterogenic distribution of pathogenic strains, as well as emerging antibiotic resistance, require the development of a broadly protective vaccine. All Shigella spp. utilize a type III secretion system (TTSS) to initiate infection. The type III secretion apparatus (TTSA) is the molecular needle and syringe that form the energized conduit between the bacterial cytoplasm and the host cell to transport effector proteins that manipulate cellular processes to benefit the pathogen. IpaB and IpaD form a tip complex atop the TTSA needle and are required for pathogenesis. Because they are common to all virulent Shigella spp., they are ideal candidate antigens for a subunit-based, broad-spectrum vaccine. We examined the immunogenicity and protective efficacy of IpaB and IpaD, alone or combined, coadministered with a double mutant heat-labile toxin (dmLT) from Escherichia coli, used as a mucosal adjuvant, in a mouse model of intranasal immunization and pulmonary challenge. Robust systemic and mucosal antibody- and T cell-mediated immunities were induced against both proteins, particularly IpaB. Mice immunized in the presence of dmLT with IpaB alone or IpaB combined with IpaD were fully protected against lethal pulmonary infection with Shigella flexneri and Shigella sonnei. We provide the first demonstration that the Shigella TTSAs IpaB and IpaD are promising antigens for the development of a cross-protective Shigella vaccine.

Original languageEnglish
Pages (from-to)1222-1231
Number of pages10
JournalInfection and Immunity
Volume80
Issue number3
DOIs
StatePublished - Mar 2012
Externally publishedYes

Fingerprint

Dive into the research topics of 'Broadly protective Shigella vaccine based on type III secretion apparatus proteins'. Together they form a unique fingerprint.

Cite this